How M.D. was paid
$3.2M in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.
Named executive officers
| Executive | Salary | Stock | Options | Incentive | Other | Total |
|---|---|---|---|---|---|---|
| David-Alexandre C. Gros, M.D.Chief Executive Officer | $613,196 | $268,660 | $1,963,080 | $349,522 | $21,690 | $3,216,148 |
| Steven Perrin, Ph.D.President and Chief Scientific Officer | $484,919 | $109,080 | $795,048 | $284,284 | $22,953 | $1,696,284 |
| Paul LittleChief Financial Officer | $479,226 | $303,000 | $572,565 | $215,172 | $22,980 | $1,592,943 |
What changed and why
- $3.2MDavid-Alexandre C. Gros received a total compensation of $3,216,148 for 2025, representing a decrease from his 2024 total of $5,644,970.
- The compensation committee introduced restricted stock units in 2025 to complement stock options and provide a balanced mix.
- 117.5%Corporate goals for 2025 were achieved at an aggregate level of 117.5% based on clinical, manufacturing, and financial performance.
- 80%Clinical development and CMC manufacturing goals were assigned a combined weighting of 80% while financial performance had 20%.
About this page
Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.